Heron Therapeutics Inc. (HRTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:80,40084,900157,600208,500391,000332,400
Cash and cash equivalents28,67715,36490,541105,13871,89831,836
Short-term investments51,73269,48867,039103,353319,074 
Other undisclosed cash, cash equivalents, and short-term investments(9)4820928300,564
Receivables60,13752,04935,49941,85039,87964,652
Inventory, net of allowances, customer advances and progress billings42,11054,57348,38241,90524,96839,032
Inventory42,11054,57348,38241,90524,96839,032
Other undisclosed current assets6,12713,91312,94221,94123,21711,164
Total current assets:188,774205,435254,423314,196479,064447,248
Noncurrent Assets
Operating lease, right-of-use asset5,4387,6459,82916,27713,754
Property, plant and equipment20,16622,16023,73422,73719,61814,677
Other noncurrent assets8,12815,71117,720346346254
Total noncurrent assets:33,73245,51651,28339,36033,71814,931
TOTAL ASSETS:222,506250,951305,706353,556512,782462,179
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54,31955,19344,92542,49154,54162,975
Employee-related liabilities15,26313,59715,24813,397
Accounts payable3,2403,2253,8035252,75816,863
Accrued liabilities51,07951,96825,85928,36936,53532,715
Debt     1,926 
Other undisclosed current liabilities25,36627,16226,13360,01240,23829,044
Total current liabilities:79,68582,35571,058102,50396,70592,019
Noncurrent Liabilities
Long-term debt and lease obligation149,490149,284157,07814,56112,242 
Long-term debt, excluding current maturities149,490149,284149,082   
Liabilities, other than long-term debt3,0415,740    
Other liabilities241241    
Operating lease, liability2,8005,4997,99614,56112,242
Other undisclosed noncurrent liabilities24,263 (7,996)(14,561)  
Total noncurrent liabilities:176,794155,024157,07814,56112,242 
Total liabilities:256,479237,379228,136117,064108,94792,019
Equity
Equity, attributable to parent(33,973)13,57277,570236,492403,835370,160
Common stock1,5031,1911,020913903782
Additional paid in capital1,870,5251,807,8551,689,9871,628,0701,568,3171,330,186
Accumulated other comprehensive income (loss)13(19)(6)25785(87)
Accumulated deficit(1,906,014)(1,795,455)(1,613,431)(1,392,748)(1,165,470)(960,721)
Total equity:(33,973)13,57277,570236,492403,835370,160
TOTAL LIABILITIES AND EQUITY:222,506250,951305,706353,556512,782462,179

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues127,044107,67286,34688,638145,96877,474
Cost of revenue
(Cost of Goods and Services Sold)
(65,105)(54,874)(46,021)(36,189)(61,619)(27,512)
Gross profit:61,93952,79840,32552,44984,34949,962
Operating expenses(172,554)(227,456)(258,153)(280,612)(295,043)(261,411)
Other undisclosed operating income      27,512
Operating loss:(110,615)(174,658)(217,828)(228,163)(210,694)(183,937)
Nonoperating income (expense)56(7,366)(2,855)8855,9455,097
Investment income, nonoperating 3,3641,6384333,6337,2595,965
Other nonoperating income (expense)560(6,530)(878)(847)1581,804
Interest and debt expense (3,868)(2,474)(2,410)(1,901)(1,472)(2,672)
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations:(114,427)(184,498)(223,093)(229,179)(206,221)(181,512)
Loss before gain (loss) on sale of properties:(223,093)(229,179)(206,221)(181,512)
Net loss:(114,427)(184,498)(223,093)(229,179)(206,221)(181,512)
Other undisclosed net income attributable to parent3,8682,4742,4101,9011,4722,672
Net loss available to common stockholders, diluted:(110,559)(182,024)(220,683)(227,278)(204,749)(178,840)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(114,427)(184,498)(223,093)(229,179)(206,221)(181,512)
Comprehensive loss:(114,427)(184,498)(223,093)(229,179)(206,221)(181,512)
Other undisclosed comprehensive income, net of tax, attributable to parent3,9002,4612,1472,0731,6442,595
Comprehensive loss, net of tax, attributable to parent:(110,527)(182,037)(220,946)(227,106)(204,577)(178,917)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: